Predictive
Oncology (NASDAQ: POAI) is a developer of highly adaptable assessment
methods for cancer patients to help guide personalized treatments. An article
discussing the company reads, “As part of Predictive Oncology’s commitment to
determining the best pathways for more individualized and effective cancer
treatment, one of its main subsidiaries – Helomics – partnered with the UK 100,000
Genomes Project (‘UK100K’) in a research study focused on driving precision
medicine to help conquer ovarian cancer. The UK100K initiative couples
whole-genome sequencing of National Health Service (NHS) patients with cancer
and other diseases to rich clinical data on drug treatments and outcomes.
Helomics’ study centers around utilizing this data to continue improving the
effectiveness of its artificial intelligence (AI)-based precision oncology
models to drive both the individualization of therapy (right drug for the right
patient) as well as the discovery of new treatments. Over the long term,
Helomics intends to seek approval to use its precision oncology models as part
of the NHS for ovarian cancer treatment.”
To view the full article, visit http://ibn.fm/JhbkF
About Predictive Oncology Inc.
Predictive Oncology operates in two business areas: first,
applying artificial intelligence to personalized medicine and drug discovery to
provide personalized medicine solutions for patients and clinicians as well as
clients in the pharmaceutical, diagnostic and biotech industries; and second,
production of the FDA-approved STREAMWAY(R) System for automated,
direct-to-drain medical fluid disposal. For more information, visit the
company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
